Acquired pure red cell aplasia: updated review of treatment

Abstract

Summary Pure red cell aplasia (PRCA) is a syndrome characterized by a severe normocytic anaemia, reticulocytopenia, and absence of erythroblasts from an otherwise normal bone marrow. Primary PRCA, or secondary PRCA which has not responded to treatment of the underlying disease, is treated as an immunologically‐mediated disease. Although vigorous immunosuppressive treatments induce and maintain remissions in a majority of patients, they carry an increased risk of serious complications. Corticosteroids were used in the treatment of PRCA and this has been considered the treatment of first choice although relapse is not uncommon. Cyclosporine A (CsA) has become established as one of the leading drugs for treatment of PRCA. However, common concerns have been the number of patients treated with CsA who achieve sustained remissions and the number that relapse. This article reviews the current status of CsA therapy and compares it to other treatments for diverse PRCAs.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 86

1. 1.

   Abkowitz JL, Powell JS, Nakamura JM, Kadin ME, Adamson JW. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. American Journal of Hematology. 1986;23:363-371.

   Not in our library10.1002/ajh.2830230408

2. 2.

   Ahern MJ, Roberts-Thomson PJ, Bradley J, Story C, Seshadri P. Phenotypic and genotypic analysis of mononuclear cells from patients with Felty's syndrome. Annals of the Rheumatic Diseases. 1990;49:103-106.

   Not in our library10.1136/ard.49.2.103

3. 3.

   Bassan R, lntrona M, Rambaldi A, Viero P, Chisesi T, Mantovani A, Barbui T. Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity. Scandinavian Journal of Haematology. 1986;37:91-96.

   Not in our library10.1111/j.1600-0609.1986.tb01779.x

4. 4.

   Batlle M, Ribera JM, Oriol A, Plensa E, Millá F, Feliu E. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia. British Journal of Haematology. 2002;118:1192-1193.

   Not in our library10.1046/j.1365-2141.2002.36892.x

5. 5.

   Battiwalla M, Melenhorst J, Saunthararajah Y, Nakamura R, Molldrem J, Young NS, Barrett AJ. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. British Journal of Haematology. 2003;123:449-453.

   Not in our library10.1046/j.1365-2141.2003.04613.x

6. 6.

   Bladford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2004;5:559-569.

   Not in our library10.1517/14622416.3.2.229

7. 7.

   Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. The New England Journal of Medicine. 2002;346:469-475.

   Not in our library10.1056/nejmoa011931

8. 8.

   Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney International. 1995;47:1130-1135.

   Not in our library10.1038/ki.1995.161

9. 9.

   Chan WC, Catovsky D, Foucar K, Montserrat E. T-Cell Large Granular Lymphocyte Leukaemia: World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. 2001;197-198.

   Not in our library

10. 10.

    Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87:4831-4838.

    Not in our library

11. 11.

    Clark AD, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood. 1984;63:277-286.

    Not in our library

12. 12.

    Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. The Journal of the American Medical Association. 1986;255:2315-2319.

    Not in our library

13. 13.

    Dessypris EN. Pure Red Cell Aplasia. 1988.

    Not in our library

14. 14.

    Dessypris EN, Lipton JM, Greer JP, Foerster J, Lukens JN, Rogers GM, Paraskevas MD, Glader B. Red cell aplasia. Wintrobe's Clinical Hematology. 2004;1421-1427.

    Not in our library

15. 15.

    Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994;84:1620-1627.

    Not in our library

16. 16.

    Dungarwalla M, Marsh JCW, Tooze JA, Lucas G, Ouwehand W, Pettengell R, Dearden CE, Gordon Smith EC, Elebute MO. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Annals of hematology. 2007;86:191-197.

    Not in our library10.1007/s00277-006-0202-5

17. 17.

    Firkin FC, Maher D. Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia. European Journal of Haematology. 1988;41:212-217.

    Not in our library10.1111/j.1600-0609.1988.tb01183.x

18. 18.

    Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. British Journal of Haematology. 2000;111:1010-1122.

    Not in our library10.1046/j.1365-2141.2000.02429.x

19. 19.

    Frickhofen N, Abkowitz JL, Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, Cohen R, Halperin I, King L, Mintzer D, Cohen B, Young NS. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Annals of Internal Medicine. 1990;113:926-933.

    Not in our library10.7326/0003-4819-113-12-926

20. 20.

    Garcia Vela JA, Monteserin MC, Oña F, Barea LM, Lastra A, Pérez V. Cyclosporine A used as a single drug in the treatment of pure red cell aplasia associated with thymoma. American Journal of Hematology. 1993;42:238-239.

    Not in our library10.1002/ajh.2830420229

21. 21.

    Gerli R, Paganelli R, Cossarizza A, Muscat C, Piccolo G, Barbieri D, Mariotti S, Monti D, Bistoni O, Raiola E, Venanzi FM, Bertotto A, Franceschi C. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. Journal of Allergy and Clinical Immunology. 1999;103:865-872.

    Not in our library10.1016/s0091-6749(99)70431-8

22. 22.

    Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood. 2002;99:1092-1094.

    Not in our library10.1182/blood.v99.3.1092

23. 23.

    Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001;98:483-485.

    Not in our library10.1182/blood.v98.2.483

24. 24.

    Go RS, Lust JA, Phyliky RL. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Seminars in Hematology. 2003;40:196-200.

    Not in our library10.1016/s0037-1963(03)00140-9

25. 25.

    Gonzales-Chambers R, Przepiorka D, Winkelstein A, Agarwal A, Starz TW, Kline WE, Hawk H. Lymphocyte subsets associated with T cell receptor P-chain gene rearrangement in patients with rheumatoid arthritis and neutropenia. Arthritis & Rheumatism. 1992;35:516-520.

    Not in our library10.1002/art.1780350505

26. 26.

    Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, Rai KR. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092-2095.

    Not in our library10.1038/sj.leu.2402676

27. 27.

    Hale G. The CD52 antigen and development of the Campath antibodies. Cytotherapy. 2001;3:137-143.

    Not in our library10.1080/146532401753174098

28. 28.

    Hamidou MA, Sadr FB, Lamy T, Raffi F, Grolleau JY, Barrier JH. Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. American Journal of Medicine. 2000;108:730-732.

    Not in our library10.1016/s0002-9343(00)00406-x

29. 29.

    Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260-2262.

    Not in our library

30. 30.

    Herbert KE, Prince HM, Westerman DA. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood. 2003;101:1654.

    Not in our library10.1182/blood-2002-09-2923

31. 31.

    Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K, Fujisawa S, Yonemura Y, Kawano F, Omine M, Ozawa K, for the PRCA Collaborative Study Group. Long-Term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA collaborative study group. Haematologica. 2008;93:27-33.

    Not in our library10.3324/haematol.11655

32. 32.

    Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000;96:3872-3879.

    Not in our library

33. 33.

    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Annals of Internal Medicine. 1992;116:488-498.

    Not in our library10.7326/0003-4819-116-6-488

34. 34.

    Isobe Y, Sugimoto K, Shiraki Y, Nishitani M, Koike K, Oshimi K. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. American Journal of Hematology. 2004;77:370-373.

    Not in our library10.1002/ajh.20200

35. 35.

    Kaznelson P. Zur Entstehung der Blutplättchen. Verhandlungen der Deutschen Gesellschaft Fur Innere Medizin. 1922;34:557-558.

    Not in our library

36. 36.

    Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.

    Not in our library10.1182/blood.v99.10.3554

37. 37.

    Krantz SB, Kao V. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proceedings of the National Academy of Sciences of the United States of America. 1967;58:493-500.

    Not in our library10.1073/pnas.58.2.493

38. 38.

    Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87:3000-3006.

    Not in our library

39. 39.

    Lamy T, Loughran TP. Large granular lymphocyte leukemia. Cancer Control. 1998;5:25-33.

    Not in our library10.1177/107327489800500103

40. 40.

    Lamy T, Loughran TP. Clinical features of large granular lymphocyte leukemia. Seminars in Hematology. 2003;40:185-195.

    Not in our library10.1016/s0037-1963(03)00133-1

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.